Newland Pharmaceutical Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan '26 Jan 29, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Market Capitalization	4,999	3,873	4,163	3,850	-	-
Market Cap Growth	28.51%	-6.96%	8.12%	-	-	-
Enterprise Value	4,290	3,072	3,378	3,956	-	-
Last Close Price	12.75	9.64	10.19	9.28	-	-
PE Ratio	40.40	22.31	26.19	29.10	-	-
PS Ratio	7.46	5.33	6.39	6.14	-	-
PB Ratio	3.28	2.51	2.87	2.83	-	-
P/TBV Ratio	3.40	2.57	2.95	2.92	-	-
P/FCF Ratio	303.02	242.50	25.55	452.81	-	-
P/OCF Ratio	36.98	30.56	16.04	46.47	-	-
EV/Sales Ratio	6.40	4.23	5.19	6.31	-	-
EV/EBITDA Ratio	25.49	14.22	17.72	23.63	-	-
EV/EBIT Ratio	34.03	16.98	20.87	27.22	-	-
EV/FCF Ratio	260.01	192.33	20.73	465.21	-	-
Debt / Equity Ratio	0.00	0.00	0.00	0.00	0.31	0.35
Debt / EBITDA Ratio	0.04	0.01	0.01	0.03	0.80	0.69
Debt / FCF Ratio	0.37	0.19	0.02	0.67	5.34	3.57
Asset Turnover	0.39	0.42	0.41	0.57	0.86	0.90
Inventory Turnover	7.10	11.50	9.30	6.12	4.81	5.81
Quick Ratio	5.73	5.26	7.89	7.14	1.42	1.22
Current Ratio	6.30	5.51	8.29	7.61	1.82	1.51
Return on Equity (ROE)	8.07%	11.56%	11.19%	14.92%	31.91%	46.93%
Return on Assets (ROA)	4.52%	6.61%	6.44%	8.25%	14.32%	18.59%
Return on Invested Capital (ROIC)	13.21%	23.81%	23.31%	24.30%	27.06%	41.41%
Return on Capital Employed (ROCE)	8.00%	11.30%	11.00%	10.50%	30.50%	41.50%
Earnings Yield	2.47%	4.48%	3.82%	3.44%	-	-
FCF Yield	0.33%	0.41%	3.91%	0.22%	-	-
Dividend Yield	2.24%	2.96%	2.00%	1.83%	-	-
Payout Ratio	90.55%	46.08%	41.94%	5.12%	31.92%	45.98%
Buyback Yield / Dilution	-0.39%	-0.39%	-29.52%	-2.59%	-0.64%	-0.34%
Total Shareholder Return	1.89%	2.57%	-27.51%	-0.75%	-0.64%	-0.34%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.